Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Homebuilders knocked lower by remarks from Carney

Tue, 14th Jul 2015 13:09

(ShareCast News) - Bank of England Governor Mark Carney told the Treasury Select Committee Bank Rate may be headed higher a little bit sooner than markets anticipated, sending stocks - especially homebuilders - listed on the second tier index promptly lower.As of 12:13 the top flight index was off by 19.22 points to 6,718.36 and the FTSE 250 lower by a hefty 141.80 points to 17,567.33.In testimony to the Committee Carney said that, "the point at which interest rates may begin to rise is moving closer given the performance of the economy."That sent the yield on the benchmark 10-year Gilt higher by four basis points to 2.15% and saw the pound snap higher towards 1.56 versus the US dollar."We judge these comments as supporting our view that the Bank is likely to deliver the first rate hike earlier than the current market pricing of May 2016. Our forecast is for a February 2016 move," economists at BNP Paribas said in a research report e-mailed to clients.Subdued core inflation in the UKHis remarks came after the latest CPI figures from ONS revealed that core inflation in the UK slipped a tad in June, to a 0.8% year-on-year pace after a reading of 0.9% in May - the joint lowest print since March 2001.Nevertheless, "this weakness continues to largely reflect cheaper goods imports. Inflation in the services sector, while below its average of 3.5% over the last decade, was a much stronger 2.2%," Samuel Tombs, Senior UK economist at Capital Economics pointed out.The headline consumer price index was flat versus a year ago, after a rise of just 0.1% in May, as expected by economists."We believe it is most likely that consumer price inflation will hover around zero through the summer and then start heading gradually but decisively up from September. There is obviously the risk that there could be another very brief dip into deflation if oil prices extend their current softening," Dr.Howard Archer, chief UK+European economist at IHS Global Insight explained to clients.All eyes on AthensActing as a backdrop, all eyes were on the parliament in Athens and whether it approve the list of reforms asked of it by creditors.That came amid an urgent need for fresh funds by Greece to meet a 20 July payment of €3.5bn falling due to the European Central Bank and to recapitalise the country's banks and restore the flow of credit in the economy."Capital control implementation can be swift, but its full removal is a lengthy process," Goldman Sachs told clients, adding that a normally functioning banking sector could be expected immediately.Defence sector finds a bidShares in defence and aerospace engineer Meggitt rose on Tuesday following a report in the Financial Times that a merger with Cobham might be on the cards. Atif Latif, director of trading at Guardian Stockbrokers, said he sees the rationale of a tie-up between the two as a defence play.Analysts at Deutsche Bank upgraded their rating for Sky from 'hold' to 'buy' and raised estimates for 2017 by 20% more than consensus. In a note to clients, Deutsche Bank said the FTSE 250 firm was the best positioned in Europe to capitalise on growth areas related to online video.Shares in homebuilders such as Taylor Wimpey, Barratt Developments and Persimmon were all knocked lower by Carney's remarks.AstraZeneca's Iressa drug, which is used in the treatment of metastatic non-small cell lung cancer (NSCLC), has been approved by the US Food and Drug Administration.Iressa is approved in 91 countries for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor mutation-positive NSCLC, which is the most common type of lung cancer.Miner BHP Billiton reported that director Sir John Buchanan died on Monday, having served on the board from 2003 up until the time of his death. Buchanan, who was the senior independent director of Anglo-Australian giant, "provided wise counsel to his fellow directors and to management, and made an invaluable contribution to BHP Billiton," said chairman Jac Nasser.Market MoverstechMARK 3,173.01 -0.20%FTSE 100 6,717.31 -0.31%FTSE 250 17,563.25 -0.82%FTSE 100 - RisersSky (SKY) 1,113.00p +3.25%Meggitt (MGGT) 478.40p +1.68%Reed Elsevier (REL) 1,095.00p +0.92%International Consolidated Airlines Group SA (CDI) (IAG) 553.50p +0.82%Unilever (ULVR) 2,904.00p +0.80%British American Tobacco (BATS) 3,642.00p +0.69%Carnival (CCL) 3,494.00p +0.60%Lloyds Banking Group (LLOY) 85.76p +0.54%Morrison (Wm) Supermarkets (MRW) 178.80p +0.45%Hikma Pharmaceuticals (HIK) 2,073.00p +0.34%FTSE 100 - FallersTaylor Wimpey (TW.) 185.80p -3.18%Barratt Developments (BDEV) 624.00p -2.73%Persimmon (PSN) 1,967.00p -2.33%Weir Group (WEIR) 1,587.00p -2.22%GKN (GKN) 317.70p -2.10%TUI AG Reg Shs (DI) (TUI) 1,066.00p -1.93%Aberdeen Asset Management (ADN) 401.30p -1.91%Johnson Matthey (JMAT) 3,003.00p -1.54%Pearson (PSON) 1,231.00p -1.52%Marks & Spencer Group (MKS) 539.50p -1.46%FTSE 250 - RisersInternational Personal Finance (IPF) 363.30p +3.03%Evraz (EVR) 121.00p +2.89%Centamin (DI) (CEY) 59.90p +1.53%AO World (AO.) 133.20p +1.52%Greggs (GRG) 1,146.00p +1.42%NMC Health (NMC) 810.50p +1.31%Carillion (CLLN) 356.30p +1.31%Pace (PIC) 372.00p +1.20%Laird (LRD) 365.10p +1.11%Telecom Plus (TEP) 1,055.00p +1.05%FTSE 250 - FallersDrax Group (DRX) 248.50p -5.08%Tullow Oil (TLW) 288.80p -4.47%Hiscox Limited (CDI) (HSX) 869.00p -3.87%Man Group (EMG) 151.70p -3.80%Bellway (BWY) 2,304.00p -3.52%Hunting (HTG) 518.50p -3.36%Bovis Homes Group (BVS) 1,116.00p -3.21%Berkeley Group Holdings (The) (BKG) 3,258.00p -2.78%Just Retirement Group (JRG) 173.10p -2.75%Paragon Group Of Companies (PAG) 384.10p -2.61%
More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.